tiprankstipranks
Trending News
More News >
Fuji Pharma Co., Ltd. (JP:4554)
:4554

Fuji Pharma Co., Ltd. (4554) AI Stock Analysis

Compare
0 Followers

Top Page

JP

Fuji Pharma Co., Ltd.

(Frankfurt:4554)

Rating:70Outperform
Price Target:
¥1,427.00
▲(8.68%Upside)
Fuji Pharma's strengths lie in its strong financial performance and attractive valuation metrics, suggesting an undervalued stock with income potential. However, mixed technical indicators and challenges in cash flow management temper the overall score. Focus on cash flow improvement and monitoring technical trends could enhance its investment appeal.

Fuji Pharma Co., Ltd. (4554) vs. iShares MSCI Japan ETF (EWJ)

Fuji Pharma Co., Ltd. Business Overview & Revenue Model

Company DescriptionFuji Pharma Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceutical products in Japan and internationally. The company offers injection agents, internal drugs, drugs for external use, and diagnostic products. It also provides medical care for women; in vitro diagnostics, acute medical care products, and curative medicines; and information regarding pharmaceuticals and health. Fuji Pharma Co., Ltd. was incorporated in 1965 and is headquartered in Tokyo, Japan.
How the Company Makes MoneyFuji Pharma Co., Ltd. generates revenue through the sale of its pharmaceutical products, which include branded and generic drugs. The company's revenue streams are primarily driven by its offerings in women's healthcare, such as hormone medications and fertility treatments, as well as diagnostic drugs used in medical imaging. Additionally, Fuji Pharma leverages its research and development capabilities to innovate and expand its product line, further supporting its income. The company may also engage in strategic partnerships and collaborations with other pharmaceutical firms to enhance its market presence and share technological advancements, thereby contributing to its revenue growth.

Fuji Pharma Co., Ltd. Financial Statement Overview

Summary
Fuji Pharma shows strong revenue growth and solid balance sheet metrics, reflecting financial stability. However, challenges in maintaining net profit margins and managing cash flow indicate areas needing strategic improvement.
Income Statement
82
Very Positive
Fuji Pharma has demonstrated strong revenue growth with a notable increase from the previous period. The gross profit margin and EBIT margin remain solid at 40.3% and 10.9%, respectively, indicating effective cost management and operational efficiency. However, the net profit margin decreased from 13.3% to 9.1% TTM, reflecting some challenges in maintaining profitability levels.
Balance Sheet
75
Positive
The company maintains a healthy equity ratio of 50.6%, providing a strong buffer against liabilities. The debt-to-equity ratio is stable at 0.64, suggesting moderate leverage. Return on equity is robust at 9.2%, indicating effective utilization of shareholders' funds. However, the increase in total debt highlights potential risks if not managed carefully.
Cash Flow
65
Positive
While operating cash flow is currently unavailable, past performance indicates some fluctuations. The free cash flow has shown significant volatility, with periods of negative free cash flow, which may impact future investment capabilities. The lack of positive free cash flow to net income ratio underscores the need for improved cash management strategies.
Breakdown
TTMSep 2024Sep 2023Sep 2022Sep 2021Sep 2020
Income StatementTotal Revenue
48.39B46.14B40.89B35.43B33.99B33.79B
Gross Profit
19.51B17.84B16.52B14.56B14.75B14.87B
EBIT
5.27B3.88B3.86B3.78B3.35B3.14B
EBITDA
8.50B12.15B7.54B6.52B5.46B5.20B
Net Income Common Stockholders
4.40B6.15B3.44B2.70B2.43B2.08B
Balance SheetCash, Cash Equivalents and Short-Term Investments
3.70B4.58B2.32B3.55B10.20B12.04B
Total Assets
94.26B90.00B85.33B75.54B64.24B61.96B
Total Debt
30.41B29.25B28.95B24.57B18.66B12.19B
Net Debt
26.72B24.67B26.62B21.02B8.46B149.00M
Total Liabilities
46.50B44.44B44.16B39.73B31.56B22.00B
Stockholders Equity
47.76B45.56B41.17B35.80B32.68B39.96B
Cash FlowFree Cash Flow
0.00-221.00M-1.98B-13.08B2.10B3.15B
Operating Cash Flow
0.004.15B1.92B-658.00M5.99B5.77B
Investing Cash Flow
0.00-1.66B-5.24B-11.27B-2.35B-2.62B
Financing Cash Flow
0.00-435.00M1.92B5.09B-5.43B450.00M

Fuji Pharma Co., Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1313.00
Price Trends
50DMA
1304.40
Positive
100DMA
1344.73
Negative
200DMA
1356.53
Negative
Market Momentum
MACD
-2.62
Negative
RSI
54.10
Neutral
STOCH
56.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4554, the sentiment is Positive. The current price of 1313 is above the 20-day moving average (MA) of 1288.10, above the 50-day MA of 1304.40, and below the 200-day MA of 1356.53, indicating a neutral trend. The MACD of -2.62 indicates Negative momentum. The RSI at 54.10 is Neutral, neither overbought nor oversold. The STOCH value of 56.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4554.

Fuji Pharma Co., Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
€31.69B9.957.01%3.62%13.46%-46.40%
54
Neutral
$5.38B3.40-45.06%3.28%16.75%-0.02%
$1.24B28.254.56%2.30%
$1.04B10.0111.38%0.01%
DEMFY
€612.91M18.064.35%2.79%
76
Outperform
¥61.26B12.79
2.17%2.06%-32.48%
73
Outperform
¥78.17B9.39
0.67%8.83%70.61%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4554
Fuji Pharma Co., Ltd.
1,313.00
-60.09
-4.38%
TRXPF
Torii Pharmaceutical Co
36.62
14.25
63.70%
TWAPF
Towa Pharmaceutical Co
25.33
6.65
35.60%
DE:MFY
Mochida Pharmaceutical Co., Ltd.
17.80
1.59
9.81%
JP:4569
KYORIN Pharmaceutical Co.,Ltd.
1,498.00
-127.99
-7.87%
JP:4886
ASKA Pharmaceutical Holdings Co., Ltd.
2,329.00
96.65
4.33%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.